Results of a new drug trial, published September 1, 2016 in Nature, are potentially the most promising yet in the fight against Alzheimer’s. The results suggests it may be possible to clear the brain of the amyloid protein that is characteristic of the disease, using the new drug aducanumab.
Although the study was small, and researchers caution that it’s far too soon to declare, there was reason to be encouraged about the trial. The longer an early-stage Alzheimer’s patient took the drug aducanumab, and the higher the dose, the less amyloid protein was visible in their brain a year later.
To read more about the drug trial, click here.